<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of severe atopic dermatitis (eczema) in children</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of severe atopic dermatitis (eczema) in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of severe atopic dermatitis (eczema) in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter A Lio, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Moise L Levy, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph Fowler, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 28, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Atopic dermatitis (AD) is a common, chronic, inflammatory skin disorder characterized by the presence of pruritic, eczematous dermatitis. In most patients, the disorder is managed with careful skin care practices, barrier repair strategies, topical therapies for inflammation, and the elimination of exacerbating factors. Patients with severe disease that fails to improve with conventional therapy may benefit from second-line therapies, such as phototherapy or systemic medications.</p><p>This topic reviews the causes and treatment of severe, refractory AD in children. The standard management of AD, including maintenance of skin hydration, control of pruritus, topical anti-inflammatory therapies, and management of infection, is discussed separately. The clinical manifestations and diagnosis of AD and the role of allergy in AD are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/114004.html" rel="external">"Evaluation and management of severe refractory atopic dermatitis (eczema) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1729.html" rel="external">"Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5545.html" rel="external">"Role of allergy in atopic dermatitis (eczema)"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION OF SEVERE ATOPIC DERMATITIS</span><span class="headingEndMark"> — </span>Most patients with AD have mild to moderate disease. However, a subpopulation of patients develops severe symptoms. Severe AD may be loosely described as the presence of widespread skin lesions, unremitting itching, or physically or emotionally disabling disease that significantly compromises a patient's quality of life  (<a class="graphic graphic_picture graphicRef80481" href="/d/graphic/80481.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef116080" href="/d/graphic/116080.html" rel="external">picture 2</a>). Patients with severe AD that does not respond to first-line topical therapies may be classified as having severe, refractory disease.</p><p class="headingAnchor" id="H3801860382"><span class="h1">ASSESSMENT OF SEVERITY</span><span class="headingEndMark"> — </span>Clinical studies have utilized scales for defining the severity of AD, such as the Investigator Global Assessment (IGA), the Scoring of Atopic Dermatitis (SCORAD) index, and the Eczema Area and Severity Index (EASI) [<a href="#rid1">1</a>]. Although such scales are useful for standardizing the results of research studies, they are not routinely used in clinical practice. Moreover, these measures may not reflect the disease severity as perceived by the individual patients. The Patient-Oriented Eczema Measure (POEM), a fully patient-derived and patient-assessed scale, has been proposed as a core instrument to complement the clinician-assessed scales in the evaluation of disease severity and response to treatment in patients with AD [<a href="#rid2">2</a>].</p><p>An international study involving over 1000 patients or parents of children with AD from 34 countries found that the symptoms considered to be important by 80 percent of the participants included itch, pain/soreness, skin feeling hot or inflamed, bleeding, involvement of visible or sensitive body sites, cracks, sleep difficulties, amount of the body affected, and weeping/oozing [<a href="#rid3">3</a>]. A practical guide to visual assessment of eczema severity that also includes the evaluation of disease impact on quality of life and psychosocial well-being has been proposed by the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nice.org.uk%2Fguidance%2Fcg57%2Fresources%2Fatopic-eczema-in-under-12s-diagnosis-and-management-975512529349&amp;token=4DwsUnU%2ByHseZwT%2BXceADKRry%2Bzhx8AIAeZ7oX0Y9mNCuaHR8zOg7aAVuNNwt88wJcgoZtIaOmtNFJZ683tRqMbt6zSqShVDvt0tisJaQ%2F%2F%2BsKLWThTsIML%2BYegtifgPKwTUOrO4iKktYDPZFMEFNQ%3D%3D&amp;TOPIC_ID=1726" target="_blank">United Kingdom National Institute for Health and Care Excellence</a>:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild</strong> – Areas of dry skin, infrequent itching (with or without small areas of redness); little impact on everyday activities, sleep, and psychosocial well-being.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate</strong> – Areas of dry skin, frequent itching, redness (with or without excoriation and localized skin thickening); moderate impact on everyday activities and psychosocial well-being, frequently disturbed sleep.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe</strong> – Widespread areas of dry skin, incessant itching, redness (with or without excoriation, extensive skin thickening, bleeding, oozing, cracking, and alteration of pigmentation); severe limitation of everyday activities and psychosocial functioning, nightly loss of sleep.</p><p></p><p class="headingAnchor" id="H3"><span class="h1">POTENTIAL CAUSES OF REFRACTORY DISEASE</span><span class="headingEndMark"> — </span>Circumstances that may contribute to severe or refractory AD include financial considerations, poor adherence or incorrect use of medications, presence of environmental exacerbating factors, secondary infection, and hypersensitivity reactions to topical treatments or other allergens  (<a class="graphic graphic_table graphicRef66729" href="/d/graphic/66729.html" rel="external">table 1</a>). Prior to initiating second-line treatments for AD, clinicians should ensure that severe, refractory disease is not a result of the presence of an avoidable or treatable factor.</p><p class="headingAnchor" id="H4"><span class="h2">Poor adherence/incorrect medication use</span><span class="headingEndMark"> — </span>For many patients, a lack of adherence to the treatment regimen and basic skin care techniques contributes to persistent disease. Over 50 percent of patients with AD do not administer treatment as recommended by their clinicians [<a href="#rid4">4-6</a>]. Specific reasons for inadequate application of treatment include financial considerations, concerns about medication side effects, patient dislike of topical preparations, and insufficient time for clinicians to educate patients about skin care [<a href="#rid7">7</a>].</p><p>Topical corticosteroid phobia, defined as a concern or fear about using topical corticosteroids, is common, with a prevalence among patients and caregivers ranging from 20 to over 80 percent worldwide [<a href="#rid8">8-10</a>]. Corticosteroid phobia is likely a contributing cause of poor adherence to treatment and treatment failure among patients with AD.</p><p class="headingAnchor" id="H921686810"><span class="h2">Exacerbating factors/environmental triggers</span><span class="headingEndMark"> — </span>Prior to initiating second-line treatments for AD, clinicians should ensure that severe, refractory disease is not a result of the presence of an avoidable or treatable exacerbating factor. Circumstances that may contribute to severe or refractory AD include noncompliance with conventional therapy, secondary infection, hypersensitivity reactions to topical treatments, and exposure to triggers of disease flares.</p><p>Exacerbating factors for AD may include low humidity environments, xerosis (dry skin), overheating of skin, emotional stress, and exposure to irritating substances, such as harsh chemicals or soaps. Avoiding these factors is helpful for avoiding acute flares as well as for long-term management, although this is not always possible. (See  <a class="medical medical_review" href="/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Infection</span><span class="headingEndMark"> — </span>Patients with AD are at an increased risk for secondary cutaneous bacterial, viral, and dermatophyte infections. The possibility of secondary infection should be considered in patients with skin lesions that appear refractory to conventional therapy. In particular, clinicians should be aware of the possibility of <em>Staphylococcus aureus</em> and herpes simplex virus (HSV) infections. </p><p>Colonization with <em>S. aureus</em> occurs more frequently in individuals with AD than in the general population, and <em>S. aureus</em> is a common cause of secondary infection in these patients. The presence of purulence or honey-colored crusts suggests <em>S. aureus</em> infection. Even in the absence of overt infection, colonization by <em>S. aureus</em> may be an exacerbating factor for AD. (See  <a class="medical medical_review" href="/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)", section on 'Staphylococcus aureus'</a>.)</p><p>Secondary HSV infection (eczema herpeticum) may also occur and, rarely, may lead to life-threatening dissemination of HSV in patients with AD. Punched-out erosions, hemorrhagic crusts, and vesicles are indicators of this infection. Rarely, coxsackie virus and vaccinia virus (in <a class="drug drug_general" data-topicid="10175" href="/d/drug information/10175.html" rel="external">smallpox vaccine</a>) can give a similar clinical picture [<a href="#rid11">11,12</a>]. (See  <a class="medical medical_review" href="/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)", section on 'Viral infections'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Hypersensitivity reactions to treatment</span><span class="headingEndMark"> — </span>Delayed hypersensitivity reactions to contact allergens in topical emollients or medications are another cause of an apparent lack of response to treatment. Allergic contact dermatitis can be caused by vehicles or active ingredients in emollients (eg, <a class="drug drug_general" data-topicid="101844" href="/d/drug information/101844.html" rel="external">lanolin</a>, propylene glycol, fragrances, preservatives), topical immunosuppressive medications (eg, corticosteroids, calcineurin inhibitors), and topical antibiotics (eg, <a class="drug drug_general" data-topicid="9052" href="/d/drug information/9052.html" rel="external">bacitracin</a>, <a class="drug drug_general" data-topicid="9686" href="/d/drug information/9686.html" rel="external">neomycin</a>) [<a href="#rid13">13-19</a>].</p><p>Contact allergy to a topical emollient, medication, or other allergen (eg, nickel) should be considered when patients present with AD that fails to respond to, or appears to worsen, with these therapies [<a href="#rid19">19,20</a>]. The identification and elimination of a contact allergen can lead to rapid clinical improvement in affected individuals. If a contact allergy is suspected, patch testing should be performed to identify the responsible allergen. (See  <a class="medical medical_review" href="/d/html/1727.html" rel="external">"Overview of dermatitis (eczematous dermatoses)", section on 'Allergic contact dermatitis'</a> and  <a class="medical medical_review" href="/d/html/1731.html" rel="external">"Allergic contact dermatitis in children"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Food and environmental allergies</span><span class="headingEndMark"> — </span>In some cases, patients with refractory AD may have undiagnosed food or environmental allergies that are worsening their disease. It is therefore important to exclude immediate and delayed hypersensitivity through allergy testing (skin prick testing, specific immunoglobulin E [IgE] measurement, and patch testing). However, evidence of allergen sensitization is not proof of clinically relevant allergy. Confirming clinical reactivity is especially important when food allergies are suspected in young children since avoidance of food allergens can result in less than optimal nutritional intake. Additionally, there is some evidence that food avoidance may actually induce sensitization, including an increased risk of developing anaphylaxis [<a href="#rid21">21,22</a>].</p><p>The role of allergy in AD is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5545.html" rel="external">"Role of allergy in atopic dermatitis (eczema)", section on 'Food allergies'</a> and  <a class="medical medical_review" href="/d/html/5545.html" rel="external">"Role of allergy in atopic dermatitis (eczema)", section on 'Environmental allergies'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Incorrect diagnosis</span><span class="headingEndMark"> — </span>An incorrect diagnosis may account for a failure to respond to conventional therapy. The possibility of other disorders that may present with clinical features that resemble AD should be considered. These may include conditions such as cutaneous T cell lymphoma, autoimmune disorders, and nutritional or immune system deficiencies  (<a class="graphic graphic_table graphicRef50324" href="/d/graphic/50324.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H1199440171"><span class="h1">REFERRAL</span><span class="headingEndMark"> — </span>Patients with refractory AD should be seen by a specialist (eg, dermatologist, allergist) familiar with second-line treatments, such as phototherapy and systemic immunosuppressive and immunomodulating agents. Because of the paucity of randomized trials addressing the management of refractory AD in the pediatric age group, however, there is a wide variability among clinicians in the use of second-line therapies for children with severe disease [<a href="#rid23">23,24</a>].</p><p class="headingAnchor" id="H1167974147"><span class="h1">OUR APPROACH</span></p><p class="headingAnchor" id="H123823584"><span class="h2">Initial management</span><span class="headingEndMark"> — </span>Because most of the second-line therapies for AD have potential adverse effects and nearly all are off-label for this indication in children, patients should be selected for these treatments only when conventional topical therapy does not provide sufficient improvement. Thus, after excluding the factors potentially associated with recalcitrant disease, we attempt a more intensive topical treatment with wet wraps for several days (see <a class="local">'Potential causes of refractory disease'</a> above). This will help identify those children who are candidates for second-line therapies.</p><p class="headingAnchor" id="H1036932978"><span class="h3">Wet wraps</span><span class="headingEndMark"> — </span>For children with persistent, severe AD despite optimal treatment with topical corticosteroids and/or topical calcineurin inhibitors and for children with an acute, generalized exacerbation of AD, we suggest wet wrap therapy with diluted medium-potency topical corticosteroids  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 3</a>) once to twice daily for 2 to 14 days. Wet wraps can be maintained for two or more hours, as tolerated, and even overnight if patients feel comfortable. Wet wraps can also be applied for a shorter time (eg, 15 to 30 minutes) two or three times per day. </p><p>Wet wraps consist of a bottom wet layer and top dry layer. They are generally applied on top of emollients or topical corticosteroids and left in place for up to 24 hours [<a href="#rid25">25</a>]. Cotton clothing in two layers may be sufficient for some cases, but elasticated cotton tubular bandages of appropriate size, which can be cut to cover any part of the body, may be more convenient in some situations [<a href="#rid26">26</a>]. Special bodysuits for wet wrap therapy for infants and toddlers are also commercially available.</p><p>Because of the increased systemic absorption of topical corticosteroids with wet wraps, some experts suggested that diluting low- to mid-potency topical corticosteroids in emollients (eg, 1:19 for face and body in infants and young children) and limiting the duration of treatment to a few days may reduce the risk of hypothalamic-pituitary-adrenal axis suppression [<a href="#rid27">27,28</a>]. Measurement of early morning fasting serum cortisol before and after treatment may be used to assess systemic absorption, although it is not generally performed for short-term use.</p><p>Data on the efficacy of wet wraps are sparse and inconsistent, due to a wide variability across studies in the treatment modality (eg, type of bandage used, frequency of application, treatment duration) and patient characteristics (eg, AD severity, body area involved) [<a href="#rid29">29</a>]. While several observational studies and a few small randomized trials support their efficacy as a short-term treatment (2 to 14 days) to induce a rapid remission in children with severe disease, other studies suggest that wet wraps are as effective as conventional treatment with topical corticosteroids and emollients [<a href="#rid25">25,30,31</a>]. Adverse effects include increased systemic absorption of topical corticosteroids, general discomfort, chills, and folliculitis. Temporary decreases in early morning serum cortisol levels have been reported, although short courses (&lt;2 weeks) of use of diluted low- to mid-potency corticosteroids have not been associated with prolonged adrenal suppression [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H3576296775"><span class="h3">Proactive therapy</span><span class="headingEndMark"> — </span>Once the flare has subsided, patients can resume topical therapy with a medium-potency topical corticosteroid and/or topical calcineurin inhibitor (<a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> 0.03 or 0.1% or <a class="drug drug_general" data-topicid="10162" href="/d/drug information/10162.html" rel="external">pimecrolimus</a> 1%) and/or topical <a class="drug drug_general" data-topicid="111394" href="/d/drug information/111394.html" rel="external">crisaborole</a> twice daily for two weeks and then intermittently (eg, for two consecutive days per week or every other day) as a proactive therapy to prevent exacerbations [<a href="#rid32">32</a>].</p><p>Topical <a class="drug drug_general" data-topicid="17096" href="/d/drug information/17096.html" rel="external">ruxolitinib</a> (a Janus kinase [JAK] inhibitor) has been approved for short-term treatment of mild to moderate AD in children 12 years and older and represents another topical nonsteroidal agent that may be useful prior to consideration of systemic therapy [<a href="#rid33">33,34</a>]. Importantly, there are significant warnings and limitations of use, both in terms of body surface area and continuous therapy. (See  <a class="medical medical_review" href="/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)", section on 'Topical ruxolitinib'</a>.)</p><p>Emollients should be liberally used multiple times per day. (See  <a class="medical medical_review" href="/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)", section on 'Maintenance and prevention of relapses'</a>.)</p><p>If a patient does not respond to proactive therapy, our next line of therapy is <a class="drug drug_general" data-topicid="112484" href="/d/drug information/112484.html" rel="external">dupilumab</a>.</p><p class="headingAnchor" id="H1375654620"><span class="h3">Dupilumab</span><span class="headingEndMark"> — </span>For children older than six months of age with refractory AD, we suggest <a class="drug drug_general" data-topicid="112484" href="/d/drug information/112484.html" rel="external">dupilumab</a> therapy rather than other immunosuppressive therapy. There are three dosing schedules based on weight. For children 60 kg and over, a 600 mg loading dose followed by 300 mg every two weeks is approved, exactly as is recommend for adults. For those in the 30 to 59 kg range, a 400 mg loading dose is administered, followed by 200 mg every two weeks. Finally, for those in the 15 to 29 kg range, a 600 mg loading dose is administered, followed by 300 mg every four weeks. The dosing for children six months to five years is 200 mg every four weeks for children weighing 5 to 15 kg and 300 mg for children weighing 15 to 30 kg, notably without any loading dose.</p><p><a class="drug drug_general" data-topicid="112484" href="/d/drug information/112484.html" rel="external">Dupilumab</a> is an interleukin (IL) 4 and IL-13 receptor-alpha antagonist that is approved by the US Food and Drug Administration for the treatment of children aged six months and older with moderate to severe AD not adequately controlled with topical prescription therapies. Data on the use of dupilumab in children aged six months and older and adolescents are now available [<a href="#rid35">35-39</a>]. The results of clinical trials evaluating the safety, pharmacokinetics, and efficacy of dupilumab in toddlers, children, and adolescents are comparable with those seen in the adult studies. (See  <a class="medical medical_review" href="/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)", section on 'Dupilumab'</a>.)</p><p class="headingAnchor" id="H4202261460"><span class="h2">Second-line therapies</span></p><p class="headingAnchor" id="H3146995939"><span class="h3">Phototherapy</span><span class="headingEndMark"> — </span>For older children (eg, older than six years who can cooperate with treatment) and adolescents with refractory AD for whom <a class="drug drug_general" data-topicid="112484" href="/d/drug information/112484.html" rel="external">dupilumab</a> is undesirable, not accessible, or ineffective, we suggest phototherapy with narrowband ultraviolet B (NBUVB), if feasible. NBUVB is usually administered three times per week, with a progressive protocol that increases the dose with each treatment, as tolerated. The patient is usually reassessed after 20 to 25 treatments. (See  <a class="medical medical_review" href="/d/html/13745.html" rel="external">"UVB phototherapy (broadband and narrowband)", section on 'Dosimetry and treatment protocols'</a>.) </p><p>Because of its favorable safety profile and wide availability, NBUVB is a more appropriate initial choice than other forms of phototherapy (eg, ultraviolet A1 [UVA1], psoralens plus ultraviolet A [PUVA], broadband ultraviolet B [UVB]) for the treatment of severe, refractory AD in children. (See  <a class="medical medical_review" href="/d/html/91676.html" rel="external">"UVA1 phototherapy"</a> and  <a class="medical medical_review" href="/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy"</a>.)</p><p>Data on the efficacy of NBUVB phototherapy in children with AD are limited to a few retrospective case series and one prospective study [<a href="#rid40">40-43</a>]. In a small study, 77 children (age 4 to 16 years) with psoriasis or AD were treated with NBUVB phototherapy [<a href="#rid40">40</a>]. Of 25 children with AD, 17 achieved minimal residual disease after a median of 24 treatments. In another retrospective study, 50 children with severe AD received more than 10 exposures to NBUVB [<a href="#rid43">43</a>]. Complete clearance or good improvement was reported in 30 children.</p><p>Data on the short- and long-term safety of NBUVB phototherapy in children are sparse. In one study, adverse effects included erythema, blistering, herpes simplex reactivation, and anxiety [<a href="#rid40">40</a>]. There are no studies evaluating the carcinogenic risk of phototherapy in children with AD. Although a systematic review of four studies assessing the risk of skin cancer among adults and children with psoriasis treated with NBUVB did not find an increased risk of melanoma or nonmelanoma skin cancer, patients receiving NBUVB phototherapy should be monitored with yearly skin examination [<a href="#rid44">44,45</a>].</p><p class="headingAnchor" id="H3506841804"><span class="h3">Cyclosporine</span><span class="headingEndMark"> — </span>For children and adolescents with refractory AD for whom <a class="drug drug_general" data-topicid="112484" href="/d/drug information/112484.html" rel="external">dupilumab</a> or phototherapy are inaccessible, undesirable, or ineffective, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> is our first-choice immunosuppressive agent. Cyclosporine has a rapid onset of action, and its effects can be noticed in the first few weeks of treatment. Cyclosporine is given at the dose of 3 to 5 mg/kg/day in two divided doses for two to four months. The dose can then be gradually tapered over several months (eg, by 1 mg/kg/day every one to three months) and stopped once stable improvement is achieved. Thereafter, intermittent therapy with 3 mg/kg or 5 mg/kg per day given twice weekly (eg, on Saturdays and Sundays) may be an option to prevent relapses while minimizing toxicity [<a href="#rid46">46</a>].</p><p><a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">Cyclosporine</a> has been shown to be effective in inducing remission in adults and children with severe AD [<a href="#rid47">47</a>]. In a systematic review and meta-analysis of 15 controlled and uncontrolled clinical trials including 602 adult and pediatric patients with AD who were treated with cyclosporine, the mean relative decrease in AD severity (based on AD severity scores) from baseline was 55 percent (95% CI 48-62) after six to eight weeks of continuous treatment [<a href="#rid47">47</a>]. After the first two weeks of treatment, disease severity decreased by 22 percent (95% CI 8-36) in patients treated with low-dose cyclosporine (2.5 to 3 mg/kg) and by 40 percent (95% CI 29-51) in those treated with high-dose cyclosporine (4 to 5 mg/kg). However, there was considerable heterogeneity among the individual trials regarding the dose and duration of cyclosporine therapy and the comparator (for studies that included a control group). Adverse events reported in these studies included gastrointestinal symptoms (40 percent), elevations in creatinine (11 percent), and newly diagnosed infections (6 percent). Headache and paresthesias were also common. Adverse events were more common in patients receiving higher doses of cyclosporine. In the three trials that reported on relapse rates after stopping therapy, approximately 50 percent of patients relapsed within two weeks. </p><p>Renal and hepatic function must be monitored during treatment. <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">Cyclosporine</a> trough levels should be monitored if the clinical response is inadequate [<a href="#rid48">48</a>]. Adverse effects include nephrotoxicity, hepatotoxicity, hypertension, hypertrichosis, increased risk of infection, and malignancy. (See  <a class="medical medical_review" href="/d/html/7995.html" rel="external">"Pharmacology of cyclosporine and tacrolimus"</a>.)</p><p class="headingAnchor" id="H1197580047"><span class="h3">Methotrexate</span><span class="headingEndMark"> — </span>For children with severe AD in whom treatment with <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> is contraindicated or not tolerated, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> is an alternative treatment option. Methotrexate has a slow onset of action, and its effects become apparent after six to eight weeks of treatment.</p><p>We usually start with a dose of 0.5 mg/kg given orally once weekly. The dose can be gradually increased as tolerated, up to a maximum of 25 mg per week. Oral supplementation with <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> 1 mg per day is recommended to reduce <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> toxicity without loss of efficacy [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate"</a>.)</p><p><a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> is a <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> antagonist that inhibits transmethylation reactions and promotes release of adenosine. The anti-inflammatory effects of methotrexate may be due to the inhibition of lymphocyte proliferation and to the anti-inflammatory activity of adenosine. Methotrexate is generally well tolerated. Adverse effects include gastrointestinal upset, hepatotoxicity, bone marrow suppression, and, very rarely, acute idiopathic pulmonary fibrosis. </p><p>Studies of <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> for the treatment of AD in children are limited to a few retrospective studies [<a href="#rid50">50-55</a>] and one small randomized trial [<a href="#rid56">56</a>]. The quality of these studies is generally low, with high variability in the dose and duration of treatment, outcome measurement, and length of follow-up [<a href="#rid57">57</a>]. Of note, in the only randomized trial, the doses of methotrexate and <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> were likely subtherapeutic [<a href="#rid56">56</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a small randomized unblinded trial, low-dose <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (7.5 mg/week) was compared with low-dose <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> (2.5 mg/kg/day) in 40 children aged 8 to 14 years with severe AD (who had failed topical therapy) [<a href="#rid56">56</a>]. The primary outcome was the mean change in Scoring of Atopic Dermatitis (SCORAD) after 12 weeks of treatment. At week 12, the mean absolute reduction in SCORAD was similar in the methotrexate and cyclosporine groups (26 and 25 points, respectively). Treatment was well tolerated in both groups. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study, 47 children 2 to 18 years old with severe AD were treated with a weekly dose of <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> 0.2 to 0.5 mg/kg [<a href="#rid50">50</a>]. The 44 patients who had completed at least three months of methotrexate treatment reported improvement of eczema, reduced itch, and reduced use of topical corticosteroids, as assessed by the Investigator Global Assessment (IGA) score, at three to five months. Sustained improvement was reported at 10 to 14 months among the 30 children who completed at least 10 months of treatment. Approximately 70 percent of patients experienced a mild flare-up during methotrexate therapy that was treated with topical corticosteroids, minor methotrexate dose adjustment, or both. Adverse effects were reported in 83 percent of the patients and included mild elevation of transaminases and transient hematologic abnormalities. Gastrointestinal adverse effects, including nausea, vomiting, and abdominal pain, occurred in nearly 30 percent of patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another retrospective study of 55 children (age 3 to 19.5 years) with severe, longstanding AD treated with <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> at a mean starting dose of 0.37 mg/kg, 42 patients (76 percent) showed improvement, with a reduction of the mean baseline IGA score from 4.2 to 2.9 after six to nine months of treatment [<a href="#rid54">54</a>]. Adverse effects occurred in 51 percent of patients, most commonly gastrointestinal discomfort and nausea (31 percent), followed by fatigue (26 percent) and headache (16 percent).</p><p></p><p class="headingAnchor" id="H2740579507"><span class="h2">Other therapies</span></p><p class="headingAnchor" id="H1275907174"><span class="h3">Systemic corticosteroids</span><span class="headingEndMark"> — </span>We generally avoid using systemic corticosteroids in children with severe AD. Although frequently used in clinical practice for the treatment of severe AD in children and adults [<a href="#rid58">58-60</a>], there are no high-quality studies evaluating their role in the management of AD [<a href="#rid61">61</a>]. A consensus statement published by the International Eczema Council, an international panel of 77 experts, reports that systemic corticosteroids should be generally avoided, particularly in children and adolescents, but can be occasionally used for a short period of time in the following circumstances [<a href="#rid62">62</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>When other options are not available or contraindicated</p><p class="bulletIndent1"><span class="glyph">●</span>As a bridge therapy to other systemic therapies or phototherapy</p><p class="bulletIndent1"><span class="glyph">●</span>For the immediate relief of acute flares</p><p class="bulletIndent1"><span class="glyph">●</span>In the most severe cases</p><p></p><p>These principles are in agreement with most clinical practice guidelines [<a href="#rid48">48,63-66</a>]. However, the dose and duration of a "short course" of systemic corticosteroids have not been determined. The European Task Force on Atopic Dermatitis/European Academy of Dermatology and Venereology Task Force position statement on the treatment of AD suggests that a typical regimen of systemic corticosteroids might be <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> 0.5 mg/kg per day for one to two weeks tapered over one month [<a href="#rid64">64</a>]. </p><p>Because of the many and potentially severe adverse effects of systemic corticosteroids in children, including adrenal suppression, weight gain, growth suppression, and increased susceptibility to infection, their use is <strong>not</strong> recommended for the long-term control of AD [<a href="#rid67">67,68</a>]. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p class="headingAnchor" id="H3903156785"><span class="h3">Mycophenolate mofetil</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil inhibits T and B cell proliferation via the inhibition of inosine monophosphatase dehydrogenase, a key enzyme involved in de novo purine synthesis. Studies of mycophenolate mofetil for the treatment of AD in children are limited. A number of small, uncontrolled studies have reported efficacy in adults with AD [<a href="#rid69">69-72</a>]. Two retrospective case series evaluated the use of the drug in children [<a href="#rid73">73</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In one report of 14 children treated with an initial dose of <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil of 12 to 40 mg/kg per day and up to 75 mg/kg per day (maximum dose 3 g/day), disease improvement occurred in all but one; the initial response was noted within eight weeks of treatment [<a href="#rid73">73</a>]. Treatment was well tolerated in all patients. Two patients experienced transient, mild gastrointestinal disturbance during the initial week of treatment, one patient had a history of recurrent herpes simplex viral infections, and two had recurrent bacterial superinfections requiring systemic antibiotic therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another report, 12 children were treated with <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil 20 to 40 mg/kg per day for 0.5 to 20 months [<a href="#rid74">74</a>]. Significant improvement was reported in eight patients and no response in four. Adverse effects included decreased hemoglobin level in one patient and cutaneous infections in three.</p><p></p><p>Adverse effects of <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil include gastrointestinal disturbances, myelosuppression, and infections.</p><p class="headingAnchor" id="H3889583671"><span class="h3">Azathioprine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">Azathioprine</a> is an antagonist of purine metabolism that inhibits T cell proliferation. Its catabolism and concurrent production of active metabolites is regulated by the levels of thiopurine methyltransferase (TPMT), which vary among individuals according to common allelic polymorphisms. Evidence supporting the use of azathioprine in children with AD is limited to a few observational studies [<a href="#rid74">74-78</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a small prospective study, 12 children with severe, recalcitrant AD (baseline SCORAD &gt;40) started treatment with <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> 1 to 2.5 mg/kg per day, depending on their baseline red blood cell TPMT activity, for up to 16.5 months [<a href="#rid75">75</a>]. Considerable improvement was reported in 11 of 12 children, with a mean decrease in SCORAD of 27.7 points. Treatment was generally well tolerated. One child had a transitory decrease in the absolute neutrophil count, and another had a mild increase in serum transaminase level.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study, 28 children aged 3 to 17 years were treated with <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> for 1 to 29 months [<a href="#rid74">74</a>]. Seventeen (61 percent) of patients reported significant improvement, six some improvement, and five no response. Seven patients experienced laboratory abnormalities (eg, abnormal liver function test, decreased hemoglobin concentration and white blood cell count) requiring dose adjustment. Twelve patients were transitioned to <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil for an average of 10 months after starting azathioprine. Of these patients, eight reported significant improvement, and four reported no improvement.</p><p></p><p><a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">Azathioprine</a> has numerous adverse effects, including myelosuppression, hepatotoxicity, gastrointestinal disturbances, increased susceptibility to infection, and increased risk of cancer (squamous cell carcinoma, non-Hodgkin lymphoma) especially for long-term treatments. Pretreatment determination of TPMT activity may be helpful to determine the appropriate dose and reduce the risk of myelotoxicity [<a href="#rid79">79</a>]. </p><p>Hematologic parameters and liver function tests must be monitored. In a series of 82 children (mean age 8.3 years) treated with <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> for an average time of approximately two years, 33 (40 percent) had transaminase levels ≥50 international unit/L and/or lymphocyte count &lt;1 x 10<sup>9</sup>/L or neutrophils &lt;1.5 x 10<sup>9</sup>/L after a median time of five months [<a href="#rid78">78</a>]. Five children discontinued azathioprine because of adverse effects.</p><p class="headingAnchor" id="H3403855837"><span class="h3">Omalizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10251" href="/d/drug information/10251.html" rel="external">Omalizumab</a> is a recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody that binds IgE with high affinity and is approved for the treatment of moderate to severe asthma inadequately controlled by inhaled corticosteroids in children aged six years or older with IgE levels up to 1500 international units/mL. Limited studies of omalizumab for AD have provided conflicting results [<a href="#rid80">80</a>].</p><p>A previous small, randomized trial including eight children with severe, refractory AD showed that <a class="drug drug_general" data-topicid="10251" href="/d/drug information/10251.html" rel="external">omalizumab</a> given at a dose of 150 to 375 mg every two to four weeks was no more effective than placebo in improving the clinical symptoms of AD, as measured with SCORAD, despite a marked reduction in the blood levels of IgE and T helper type 2 (Th2) inflammatory markers [<a href="#rid81">81</a>]. In a subsequent randomized trial including 62 children with severe AD and elevated IgE levels treated with omalizumab or placebo for 24 weeks, omalizumab was more effective than placebo in improving the clinical signs of AD (mean difference in the objective SCORAD index between the omalizumab group and placebo group -6.9, 95% CI -12.2 to -1.5, after adjusting for baseline SCORAD score, serum IgE level [≤1500 or &gt;1500 international units/mL] and age [&lt;10 or ≥10 years]) [<a href="#rid82">82</a>]. However, in this trial, omalizumab was used at much higher doses (up to 1200 mg per month), and all patients were allowed to use potent topical corticosteroids as needed throughout the study.</p><p class="headingAnchor" id="H1696648485"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112824.html" rel="external">"Society guideline links: Atopic dermatitis"</a>.)</p><p class="headingAnchor" id="H38"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15392.html" rel="external">"Patient education: Eczema (atopic dermatitis) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/7638.html" rel="external">"Patient education: Eczema (atopic dermatitis) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H39"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential causes of refractory disease </strong>– Severe atopic dermatitis (AD) remains a difficult condition to treat. Before initiating second-line treatments for AD, factors potentially associated with recalcitrant diseases should be assessed and treated. These include poor adherence to treatment, presence of environmental triggers or allergens, infected eczema, and incorrect diagnosis. (See <a class="local">'Potential causes of refractory disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial management</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children of any age with persistent, severe AD or acute, generalized exacerbation of AD, we attempt a more intensive topical treatment with wet wrap therapy with diluted, medium-potency topical corticosteroids  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 3</a>) rather than systemic treatments. Wet wraps consist of a bottom wet layer and a top dry layer. They are applied once or twice daily and can be maintained for two or more hours, as tolerated, and even overnight if patients feel comfortable. Wet wraps can be used until improvement occurs, usually for a few days and up to 14 days, if tolerated. Topical therapy is resumed once the flare has subsided. (See <a class="local">'Wet wraps'</a> above and <a class="local">'Proactive therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children <strong>≥6 months </strong>and adolescents who do not respond to or refuse wet wraps, we suggest <a class="drug drug_general" data-topicid="112484" href="/d/drug information/112484.html" rel="external">dupilumab</a> as first-line therapy rather than other treatments (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). The dosing schedules in children 6 months to 17 years of age are based on weight. (See <a class="local">'Dupilumab'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Second-line therapies</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children six months to six years of age </strong>–<strong> </strong>For children six months to six years of age with severe AD for whom <a class="drug drug_general" data-topicid="112484" href="/d/drug information/112484.html" rel="external">dupilumab</a> is undesirable, not accessible, or ineffective, conventional systemic immunosuppressive therapy is warranted. In this setting, we suggest oral <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> as the first-choice immunosuppressive agent rather than other immunosuppressive agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Cyclosporine is given at the dose of 3 to 5 mg/kg in two divided doses for two to four months and then gradually tapered. (See <a class="local">'Cyclosporine'</a> above.)</p><p></p><p class="bulletIndent2">For children in whom treatment with <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> is contraindicated or not tolerated, other treatment options include <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, and <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>. (See <a class="local">'Other therapies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children older than six years</strong> – For children ≥6 years and adolescents for whom <a class="drug drug_general" data-topicid="112484" href="/d/drug information/112484.html" rel="external">dupilumab</a> is undesirable, not accessible, or ineffective, we suggest narrowband ultraviolet B (NBUVB) phototherapy rather than conventional immunosuppressive agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). NBUVB is usually administered three times per week, with a progressive protocol that increases the dose with each treatment, as tolerated. (See <a class="local">'Phototherapy'</a> above.)</p><p></p><p class="bulletIndent2">If phototherapy is inaccessible, undesirable, or ineffective, alternative therapies include oral <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> or other conventional immunosuppressants (eg, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>). (See <a class="local">'Cyclosporine'</a> above and <a class="local">'Methotrexate'</a> above and <a class="local">'Other therapies'</a> above.)</p><p></p><p class="headingAnchor" id="H830406387"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Jonathan M Spergel, MD, PhD, FAAAAI, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Schmitt J, Langan S, Deckert S, et al. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol 2013; 132:1337.</a></li><li><a class="nounderline abstract_t">Spuls PI, Gerbens LAA, Simpson E, et al. Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement. Br J Dermatol 2017; 176:979.</a></li><li><a class="nounderline abstract_t">von Kobyletzki LB, Thomas KS, Schmitt J, et al. What Factors are Important to Patients when Assessing Treatment Response: An International Cross-sectional Survey. Acta Derm Venereol 2017; 97:86.</a></li><li><a class="nounderline abstract_t">Beattie PE, Lewis-Jones MS. Parental knowledge of topical therapies in the treatment of childhood atopic dermatitis. Clin Exp Dermatol 2003; 28:549.</a></li><li><a class="nounderline abstract_t">Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006; 118:226.</a></li><li><a class="nounderline abstract_t">Krejci-Manwaring J, Tusa MG, Carroll C, et al. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol 2007; 56:211.</a></li><li><a class="nounderline abstract_t">Ohya Y, Williams H, Steptoe A, et al. Psychosocial factors and adherence to treatment advice in childhood atopic dermatitis. J Invest Dermatol 2001; 117:852.</a></li><li><a class="nounderline abstract_t">Stalder JF, Aubert H, Anthoine E, et al. Topical corticosteroid phobia in atopic dermatitis: International feasibility study of the TOPICOP score. Allergy 2017; 72:1713.</a></li><li><a class="nounderline abstract_t">El Hachem M, Gesualdo F, Ricci G, et al. Topical corticosteroid phobia in parents of pediatric patients with atopic dermatitis: a multicentre survey. Ital J Pediatr 2017; 43:22.</a></li><li><a class="nounderline abstract_t">Li AW, Yin ES, Antaya RJ. Topical Corticosteroid Phobia in Atopic Dermatitis: A Systematic Review. JAMA Dermatol 2017; 153:1036.</a></li><li><a class="nounderline abstract_t">Mathes EF, Oza V, Frieden IJ, et al. "Eczema coxsackium" and unusual cutaneous findings in an enterovirus outbreak. Pediatrics 2013; 132:e149.</a></li><li><a class="nounderline abstract_t">Reed JL, Scott DE, Bray M. Eczema vaccinatum. Clin Infect Dis 2012; 54:832.</a></li><li><a class="nounderline abstract_t">Karlberg AT, Bergström MA, Börje A, et al. Allergic contact dermatitis--formation, structural requirements, and reactivity of skin sensitizers. Chem Res Toxicol 2008; 21:53.</a></li><li><a class="nounderline abstract_t">Coloe J, Zirwas MJ. Allergens in corticosteroid vehicles. Dermatitis 2008; 19:38.</a></li><li><a class="nounderline abstract_t">Iliev D, Wüthrich B. Occupational protein contact dermatitis with type I allergy to different kinds of meat and vegetables. Int Arch Occup Environ Health 1998; 71:289.</a></li><li><a class="nounderline abstract_t">Lodén M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am J Clin Dermatol 2003; 4:771.</a></li><li><a class="nounderline abstract_t">Pirker C, Möslinger T, Wantke F, et al. Ethylmercuric chloride: the responsible agent in thimerosal hypersensitivity. Contact Dermatitis 1993; 29:152.</a></li><li><a class="nounderline abstract_t">VanArsdel PP Jr, Larson EB. Diagnostic tests for patients with suspected allergic disease. Utility and limitations. Ann Intern Med 1989; 110:304.</a></li><li><a class="nounderline abstract_t">Corazza M, Mantovani L, Maranini C, et al. Contact sensitization to corticosteroids: increased risk in long term dermatoses. Eur J Dermatol 2000; 10:533.</a></li><li><a class="nounderline abstract_t">Mailhol C, Lauwers-Cances V, Rancé F, et al. Prevalence and risk factors for allergic contact dermatitis to topical treatment in atopic dermatitis: a study in 641 children. Allergy 2009; 64:801.</a></li><li><a class="nounderline abstract_t">Chang A, Robison R, Cai M, Singh AM. Natural History of Food-Triggered Atopic Dermatitis and Development of Immediate Reactions in Children. J Allergy Clin Immunol Pract 2016; 4:229.</a></li><li><a class="nounderline abstract_t">Ho HE, Chehade M. Development of IgE-mediated immediate hypersensitivity to a previously tolerated food following its avoidance for eosinophilic gastrointestinal diseases. J Allergy Clin Immunol Pract 2018; 6:649.</a></li><li class="breakAll">Nankervis H, Thomas KS, Delamere FM, et al. Scoping Systematic Review of Treatments for Eczema, NIHR Journals Library, 2016.</li><li><a class="nounderline abstract_t">Nankervis H, Thomas KS, Delamere FM, et al. What is the evidence base for atopic eczema treatments? A summary of published randomized controlled trials. Br J Dermatol 2017; 176:910.</a></li><li><a class="nounderline abstract_t">Devillers AC, Oranje AP. Efficacy and safety of 'wet-wrap' dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature. Br J Dermatol 2006; 154:579.</a></li><li class="breakAll">The Royal Children's Hospital. Wet dressings for eczema. www.rch.org.au/uploadedFiles/Main/Content/derm/Wet_dressings_eczema.pdf (Accessed on July 18, 2017).</li><li><a class="nounderline abstract_t">Oranje AP, Devillers AC, Kunz B, et al. Treatment of patients with atopic dermatitis using wet-wrap dressings with diluted steroids and/or emollients. An expert panel's opinion and review of the literature. J Eur Acad Dermatol Venereol 2006; 20:1277.</a></li><li><a class="nounderline abstract_t">Devillers AC, Oranje AP. Wet-wrap treatment in children with atopic dermatitis: a practical guideline. Pediatr Dermatol 2012; 29:24.</a></li><li><a class="nounderline abstract_t">González-López G, Ceballos-Rodríguez RM, González-López JJ, et al. Efficacy and safety of wet wrap therapy for patients with atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol 2017; 177:688.</a></li><li><a class="nounderline abstract_t">Beattie PE, Lewis-Jones MS. A pilot study on the use of wet wraps in infants with moderate atopic eczema. Clin Exp Dermatol 2004; 29:348.</a></li><li><a class="nounderline abstract_t">Hindley D, Galloway G, Murray J, Gardener L. A randomised study of "wet wraps" versus conventional treatment for atopic eczema. Arch Dis Child 2006; 91:164.</a></li><li><a class="nounderline abstract_t">Thaçi D, Reitamo S, Gonzalez Ensenat MA, et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol 2008; 159:1348.</a></li><li><a class="nounderline abstract_t">Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol 2021; 85:863.</a></li><li class="breakAll">Opzelura (ruxolitinib) cream, for topical use. US FDA approved product information; Wilmington, DE: Incyte Corporation; April 2022. https://www.opzelura.com/prescribing-information.pdf (Accessed on June 28, 2022).</li><li><a class="nounderline abstract_t">Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol 2020; 182:85.</a></li><li><a class="nounderline abstract_t">Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol 2020; 156:44.</a></li><li><a class="nounderline abstract_t">Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol 2020; 83:1282.</a></li><li><a class="nounderline abstract_t">Cork MJ, Thaçi D, Eichenfield LF, et al. Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to &lt; 12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study. Br J Dermatol 2021; 184:857.</a></li><li><a class="nounderline abstract_t">Paller AS, Siegfried EC, Simpson EL, et al. A phase 2, open-label study of single-dose dupilumab in children aged 6 months to &lt;6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. J Eur Acad Dermatol Venereol 2021; 35:464.</a></li><li><a class="nounderline abstract_t">Jury CS, McHenry P, Burden AD, et al. Narrowband ultraviolet B (UVB) phototherapy in children. Clin Exp Dermatol 2006; 31:196.</a></li><li><a class="nounderline abstract_t">Eustace K, Dolman S, Alsharqi A, et al. Use of Phototherapy in Children. Pediatr Dermatol 2017; 34:150.</a></li><li><a class="nounderline abstract_t">Tay YK, Morelli JG, Weston WL. Experience with UVB phototherapy in children. Pediatr Dermatol 1996; 13:406.</a></li><li><a class="nounderline abstract_t">Clayton TH, Clark SM, Turner D, Goulden V. The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy. Clin Exp Dermatol 2007; 32:28.</a></li><li><a class="nounderline abstract_t">Hearn RM, Kerr AC, Rahim KF, et al. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. Br J Dermatol 2008; 159:931.</a></li><li><a class="nounderline abstract_t">Archier E, Devaux S, Castela E, et al. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012; 26 Suppl 3:22.</a></li><li><a class="nounderline abstract_t">Garrido Colmenero C, Blasco Morente G, Tercedor Sánchez J. Oral Cyclosporine Weekend Therapy: A New Maintenance Therapeutic Option in Patients with Severe Atopic Dermatitis. Pediatr Dermatol 2015; 32:551.</a></li><li><a class="nounderline abstract_t">Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2007; 21:606.</a></li><li><a class="nounderline abstract_t">Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 2014; 71:327.</a></li><li><a class="nounderline abstract_t">Shea B, Swinden MV, Ghogomu ET, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol 2014; 41:1049.</a></li><li><a class="nounderline abstract_t">Dvorakova V, O'Regan GM, Irvine AD. Methotrexate for Severe Childhood Atopic Dermatitis: Clinical Experience in a Tertiary Center. Pediatr Dermatol 2017; 34:528.</a></li><li><a class="nounderline abstract_t">Deo M, Yung A, Hill S, Rademaker M. Methotrexate for treatment of atopic dermatitis in children and adolescents. Int J Dermatol 2014; 53:1037.</a></li><li><a class="nounderline abstract_t">Rahman SI, Siegfried E, Flanagan KH, Armbrecht ES. The methotrexate polyglutamate assay supports the efficacy of methotrexate for severe inflammatory skin disease in children. J Am Acad Dermatol 2014; 70:252.</a></li><li><a class="nounderline abstract_t">Roberts H, Orchard D. Methotrexate is a safe and effective treatment for paediatric discoid (nummular) eczema: a case series of 25 children. Australas J Dermatol 2010; 51:128.</a></li><li><a class="nounderline abstract_t">Anderson K, Putterman E, Rogers RS, et al. Treatment of severe pediatric atopic dermatitis with methotrexate: A retrospective review. Pediatr Dermatol 2019; 36:298.</a></li><li><a class="nounderline abstract_t">Purvis D, Lee M, Agnew K, et al. Long-term effect of methotrexate for childhood atopic dermatitis. J Paediatr Child Health 2019; 55:1487.</a></li><li><a class="nounderline abstract_t">El-Khalawany MA, Hassan H, Shaaban D, et al. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. Eur J Pediatr 2013; 172:351.</a></li><li><a class="nounderline abstract_t">Tsakok T, Flohr C. Methotrexate vs. ciclosporin in the treatment of severe atopic dermatitis in children: a critical appraisal. Br J Dermatol 2014; 170:496.</a></li><li><a class="nounderline abstract_t">Proudfoot LE, Powell AM, Ayis S, et al. The European TREatment of severe Atopic eczema in children Taskforce (TREAT) survey. Br J Dermatol 2013; 169:901.</a></li><li><a class="nounderline abstract_t">Totri CR, Eichenfield LF, Logan K, et al. Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey. J Am Acad Dermatol 2017; 76:281.</a></li><li><a class="nounderline abstract_t">Taylor K, Swan DJ, Affleck A, et al. Treatment of moderate-to-severe atopic eczema in adults within the U.K.: results of a national survey of dermatologists. Br J Dermatol 2017; 176:1617.</a></li><li><a class="nounderline abstract_t">Yu SH, Drucker AM, Lebwohl M, Silverberg JI. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J Am Acad Dermatol 2018; 78:733.</a></li><li><a class="nounderline abstract_t">Drucker AM, Eyerich K, de Bruin-Weller MS, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol 2018; 178:768.</a></li><li><a class="nounderline abstract_t">Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol 2012; 26:1176.</a></li><li><a class="nounderline abstract_t">Wollenberg A, Oranje A, Deleuran M, et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol 2016; 30:729.</a></li><li><a class="nounderline abstract_t">Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol 2013; 131:295.</a></li><li><a class="nounderline abstract_t">Saeki H, Nakahara T, Tanaka A, et al. Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016. J Dermatol 2016; 43:1117.</a></li><li><a class="nounderline abstract_t">Aljebab F, Choonara I, Conroy S. Systematic Review of the Toxicity of Long-Course Oral Corticosteroids in Children. PLoS One 2017; 12:e0170259.</a></li><li><a class="nounderline abstract_t">Caplan A, Fett N, Rosenbach M, et al. Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Ocular, cardiovascular, muscular, and psychiatric side effects and issues unique to pediatric patients. J Am Acad Dermatol 2017; 76:201.</a></li><li><a class="nounderline abstract_t">Grundmann-Kollmann M, Podda M, Ochsendorf F, et al. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol 2001; 137:870.</a></li><li><a class="nounderline abstract_t">Benez A, Fierlbeck G. Successful long-term treatment of severe atopic dermatitis with mycophenolate mofetil. Br J Dermatol 2001; 144:638.</a></li><li><a class="nounderline abstract_t">Hansen ER, Buus S, Deleuran M, Andersen KE. Treatment of atopic dermatitis with mycophenolate mofetil. Br J Dermatol 2000; 143:1324.</a></li><li><a class="nounderline abstract_t">Grundmann-Kollmann M, Korting HC, Behrens S, et al. Successful treatment of severe refractory atopic dermatitis with mycophenolate mofetil. Br J Dermatol 1999; 141:175.</a></li><li><a class="nounderline abstract_t">Heller M, Shin HT, Orlow SJ, Schaffer JV. Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients. Br J Dermatol 2007; 157:127.</a></li><li><a class="nounderline abstract_t">Waxweiler WT, Agans R, Morrell DS. Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil. Pediatr Dermatol 2011; 28:689.</a></li><li><a class="nounderline abstract_t">Caufield M, Tom WL. Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring. J Am Acad Dermatol 2013; 68:29.</a></li><li><a class="nounderline abstract_t">Hon KL, Ching GK, Leung TF, et al. Efficacy and tolerability at 3 and 6 months following use of azathioprine for recalcitrant atopic dermatitis in children and young adults. J Dermatolog Treat 2009; 20:141.</a></li><li><a class="nounderline abstract_t">Hughes R, Collins P, Rogers S. Further experience of using azathioprine in the treatment of severe atopic dermatitis. Clin Exp Dermatol 2008; 33:710.</a></li><li><a class="nounderline abstract_t">Fuggle NR, Bragoli W, Mahto A, et al. The adverse effect profile of oral azathioprine in pediatric atopic dermatitis, and recommendations for monitoring. J Am Acad Dermatol 2015; 72:108.</a></li><li><a class="nounderline abstract_t">Flohr C, Irvine AD. Systemic therapies for severe atopic dermatitis in children and adults. J Allergy Clin Immunol 2013; 132:774.</a></li><li><a class="nounderline abstract_t">Holm JG, Thomsen SF. Omalizumab for atopic dermatitis: evidence for and against its use. G Ital Dermatol Venereol 2019; 154:480.</a></li><li><a class="nounderline abstract_t">Iyengar SR, Hoyte EG, Loza A, et al. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol 2013; 162:89.</a></li><li><a class="nounderline abstract_t">Chan S, Cornelius V, Cro S, et al. Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis: The ADAPT Randomized Clinical Trial. JAMA Pediatr 2020; 174:29.</a></li></ol></div><div id="topicVersionRevision">Topic 1726 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24035157" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27858989" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27305646" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : What Factors are Important to Patients when Assessing Treatment Response: An International Cross-sectional Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12950351" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Parental knowledge of topical therapies in the treatment of childhood atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16815160" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Patient perspectives on the management of atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17224366" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11676822" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Psychosocial factors and adherence to treatment advice in childhood atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28439896" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Topical corticosteroid phobia in atopic dermatitis: International feasibility study of the TOPICOP score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28245844" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Topical corticosteroid phobia in parents of pediatric patients with atopic dermatitis: a multicentre survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28724128" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Topical Corticosteroid Phobia in Atopic Dermatitis: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23776120" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : "Eczema coxsackium" and unusual cutaneous findings in an enterovirus outbreak.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22291103" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Eczema vaccinatum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18052130" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Allergic contact dermatitis--formation, structural requirements, and reactivity of skin sensitizers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18346395" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Allergens in corticosteroid vehicles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9638487" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Occupational protein contact dermatitis with type I allergy to different kinds of meat and vegetables.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14572299" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8222628" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Ethylmercuric chloride: the responsible agent in thimerosal hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2643916" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Diagnostic tests for patients with suspected allergic disease. Utility and limitations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11056424" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Contact sensitization to corticosteroids: increased risk in long term dermatoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19183418" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prevalence and risk factors for allergic contact dermatitis to topical treatment in atopic dermatitis: a study in 641 children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26597013" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Natural History of Food-Triggered Atopic Dermatitis and Development of Immediate Reactions in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28958748" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Development of IgE-mediated immediate hypersensitivity to a previously tolerated food following its avoidance for eosinophilic gastrointestinal diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28958748" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Development of IgE-mediated immediate hypersensitivity to a previously tolerated food following its avoidance for eosinophilic gastrointestinal diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27547965" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : What is the evidence base for atopic eczema treatments? A summary of published randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16536797" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Efficacy and safety of 'wet-wrap' dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16536797" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy and safety of 'wet-wrap' dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17062046" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Treatment of patients with atopic dermatitis using wet-wrap dressings with diluted steroids and/or emollients. An expert panel's opinion and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22256990" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Wet-wrap treatment in children with atopic dermatitis: a practical guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27861727" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Efficacy and safety of wet wrap therapy for patients with atopic dermatitis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15245526" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A pilot study on the use of wet wraps in infants with moderate atopic eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16308411" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A randomised study of "wet wraps" versus conventional treatment for atopic eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18782319" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33957195" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33957195" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31595499" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31693077" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32574587" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32969489" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Dupilumab provides favourable long-term safety and efficacy in children aged≥6 to&lt;12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32893393" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A phase 2, open-label study of single-dose dupilumab in children aged 6 months to&lt;6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16487089" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Narrowband ultraviolet B (UVB) phototherapy in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28133819" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Use of Phototherapy in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8893243" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Experience with UVB phototherapy in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17305905" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18834483" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22512677" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25939958" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Oral Cyclosporine Weekend Therapy: A New Maintenance Therapeutic Option in Patients with Severe Atopic Dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17447974" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Cyclosporin in the treatment of patients with atopic eczema - a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24813298" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24737913" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28730617" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Methotrexate for Severe Childhood Atopic Dermatitis: Clinical Experience in a Tertiary Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24602088" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Methotrexate for treatment of atopic dermatitis in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24332314" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The methotrexate polyglutamate assay supports the efficacy of methotrexate for severe inflammatory skin disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20546220" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Methotrexate is a safe and effective treatment for paediatric discoid (nummular) eczema: a case series of 25 children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30811669" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Treatment of severe pediatric atopic dermatitis with methotrexate: A retrospective review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31016803" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Long-term effect of methotrexate for childhood atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23229188" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24617431" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Methotrexate vs. ciclosporin in the treatment of severe atopic dermatitis in children: a critical appraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23855450" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The European TREatment of severe Atopic eczema in children Taskforce (TREAT) survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27855965" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27943248" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Treatment of moderate-to-severe atopic eczema in adults within the U.K.: results of a national survey of dermatologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29032119" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28865094" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22813359" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Guidelines for treatment of atopic eczema (atopic dermatitis) Part II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27004560" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23374261" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Atopic dermatitis: a practice parameter update 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27076388" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28125632" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Systematic Review of the Toxicity of Long-Course Oral Corticosteroids in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28088991" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Ocular, cardiovascular, muscular, and psychiatric side effects and issues unique to pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11453805" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Mycophenolate mofetil is effective in the treatment of atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11260038" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Successful long-term treatment of severe atopic dermatitis with mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11122047" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Treatment of atopic dermatitis with mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10417549" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Successful treatment of severe refractory atopic dermatitis with mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17489974" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Mycophenolate mofetil for severe childhood atopic dermatitis: experience in 14 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21967657" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22892285" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18951236" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Efficacy and tolerability at 3 and 6 months following use of azathioprine for recalcitrant atopic dermatitis in children and young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18681884" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Further experience of using azathioprine in the treatment of severe atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25440430" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The adverse effect profile of oral azathioprine in pediatric atopic dermatitis, and recommendations for monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23993356" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Systemic therapies for severe atopic dermatitis in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30717578" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Omalizumab for atopic dermatitis: evidence for and against its use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23816920" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31764962" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis: The ADAPT Randomized Clinical Trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
